1-(2,3-dihydroxypropyl)-N-(7-fluoro-6-(2-fluoro-4-iodophenylamino)-3-methylbenzo[d]isoxazol-5-yl)cyclopropane-1-sulfonamide | 1040246-01-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚和异茚
• 英文名称: 1-(2,3-dihydroxypropyl)-N-(7-fluoro-6-(2-fluoro-4-iodophenylamino)-3-methylbenzo[d]isoxazol-5-yl)cyclopropane-1-sulfonamide
• 英文别名: 1-(2,3-dihydroxypropyl)-N-[7-fluoro-6-(2-fluoro-4-iodoanilino)-3-methyl-1,2-benzoxazol-5-yl]cyclopropane-1-sulfonamide
• CAS: 1040246-01-2
• 化学式: C₂₀H₂₀F₂IN₃O₅S
• 分子量: 579.363
• InChiKey: IPOORXIGISWGLL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  32
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  133
• 氢给体数：
  4
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  1-allyl-N-(7-fluoro-6-(2-fluoro-4-iodophenylamino)-3-methylbenzo[d]isoxazol-5-yl)cyclopropane-1-sulfonamide 在 四氧化锇 、 N-甲基吗啉氧化物 、 sodium sulfite 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 16.0h， 以57%的产率得到1-(2,3-dihydroxypropyl)-N-(7-fluoro-6-(2-fluoro-4-iodophenylamino)-3-methylbenzo[d]isoxazol-5-yl)cyclopropane-1-sulfonamide
  参考文献：
  名称：

  WO2008/89459

  摘要：

  公开号：

文献信息

• COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF
  申请人：MINER Jeffrey

  公开号：US20120136030A1

  公开（公告）日：2012-05-31

  This invention concerns combinations of inhibitors of MEK, Raf protein kinases, and other kinases including VEGFR1-3 and PDGFR-β. This invention also concerns pharmaceutical compositions comprising the compounds described herein and methods of use of the compounds and compositions described herein, including the use in the treatment and/or prevention of cancer and other hyperproliferative disorders.

  这项发明涉及MEK、Raf蛋白激酶以及其他激酶（包括VEGFR1-3和PDGFR-β）的抑制剂的组合。这项发明还涉及包括本文所描述的化合物的药物组合物，以及所述化合物和组合物的使用方法，包括用于治疗和/或预防癌症和其他过度增殖性疾病的用途。
• Inhibitors of MEK
  申请人：Vernier Jean-Michel

  公开号：US20080255133A1

  公开（公告）日：2008-10-16

  This invention concerns to N-(2-aylamino)aryl sulfonamides, which are inhibitors of MEK, methods of using such compounds in the treatment of hyperproliferative diseases, and to pharmaceutical compositions containing such compounds.

  本发明涉及N-(2-烷基氨基)芳基磺酰胺，其为MEK抑制剂，以及使用这些化合物治疗过度增生性疾病的方法，以及含有这些化合物的制药组合物。
• BIOMARKERS FOR DETERMINING EFFECTIVE RESPONSE OF TREATMENTS OF HEPATOCELLULAR CARCINOMA (HCC) PATIENTS
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20150267258A1

  公开（公告）日：2015-09-24

  This invention is directed to the use of one or more biomarkers defined as KRAS or NRAS gene for predicting the pharmaceutical efficacy or clinical response of MEK protein kinase inhibitor and/or Sorafenib or Regorafenib to be administered to a Hepatocellular carcinoma (HCC) patient. Further the invention is directed to in-vitro methods for identifying mutated-type KRAS or NRAS gene in HCC patient and kits thereof.

  本发明涉及使用一个或多个生物标志物，定义为KRAS或NRAS基因，用于预测MEK蛋白激酶抑制剂和/或SoRAfenib或RegoRAfenib对肝细胞癌（HCC）患者的药效或临床反应。此外，本发明还涉及用于识别HCC患者中突变型KRAS或NRAS基因的体外方法及其试剂盒。
• INHIBITORS OF MEK
  申请人：Koh Yung-hyo

  公开号：US20100331334A1

  公开（公告）日：2010-12-30

  This invention concerns to N-(2-aylamino)aryl sulfonamides, which are inhibitors of MEK, methods of using such compounds in the treatment of hyperproliferative diseases, and to pharmaceutical compositions containing such compounds.

  这项发明涉及N-(2-烷基氨基)芳基磺酰胺，它们是MEK的抑制剂，使用这些化合物治疗增殖过度性疾病的方法，以及含有这些化合物的药物组合物。
• METHOD OF REDUCING ADVERSE EFFECTS IN A CANCER PATIENT UNDREGOING TREATMENT WITH A MEK INHIBITOR
  申请人：THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV

  公开号：US20150265679A1

  公开（公告）日：2015-09-24

  What is described is a method for treating an adverse side effect of MEK inhibitors by administering a pharmaceutical composition comprising IFNγ to a cancer patient being treated by a MEK-inhibitor. The applicants discovered that MEK inhibitors produce unwanted visual disturbances as an adverse side effect in a significant fraction of cancer patients being treated by the drug, and that the side effect causes retinal detachment due to fluid accumulation in the eye. The method treats the retinal detachment caused by the anticancer therapeutic by providing a means of decreasing the amount of fluid present in the retina and/or subretinal space of the eye by administering the pharmaceutical composition comprising IFNγ to the basolateral side of the retinal pigment epithelium, preferably by administering the pharmaceutical composition to the anterior surface of the eye in liquid droplets.